Lonza
Lonza

Lonza Boosts Microbial Production with Major Expansion!
🌍 Lonza expands its microbial manufacturing facility in Visp, Switzerland, adding two 4,000L fermenters and a new GMP license! ✅📈🔧

2024’s Top CDMOs: Leaders and Challenges Ahead!
**Excerpt:** Discover the top 10 CDMOs for 2024! 🌟 Lonza, Thermo Fisher, and Catalent lead the way amidst industry challenges. 📈⚠️

Lonza Partners with Acumen for Alzheimer’s Breakthrough
📰 Lonza teams up with Acumen to make sabirnetug, a groundbreaking Alzheimer's therapy, at their New Hampshire facility. 👥 🧪 Sabirnetug targets toxic amyloid beta oligomers, offering hope in the fight against Alzheimer's. 💡 ⏩ Exciting collaboration to speed up Alzheimer's treatment development. Lonza Acumen AlzheimersTherapy Sabirnetug

Lonza Revolutionizes Respiratory Treatment with Advanced Pulmonary Delivery Services
📢 Lonza expands service offering for spray-dried biologics for pulmonary delivery, improving respiratory therapies and patient access. 🌬️💊🌍💪

Lonza Acquires Genentech’s $12B Biologics Site
📢 Lonza buys Genentech's CA biologics manufacturing site for $1.2B, boosting production capabilities for next-gen therapies. 🏭

Revolutionary Partnership Speeds Up mRNA Analysis!
🧪📈 Lonza and Oxford Nanopore join forces to revolutionize mRNA analysis in the fast-paced biotech sector. Exciting times ahead!

Revolutionary Partnership to Enhance mRNA Therapeutics
📢 Lonza and Oxford Nanopore collaborate to advance mRNA Therapeutics! This partnership aims to improve mRNA product analysis 👥🧬💉

Lonza’s Upcoming Approvals Will Revolutionize CGT Biz in 2024
💼Lonza is looking to strengthen its cell and gene therapy business through upcoming approvals in 2024. 🌟🔬💉💪📈🔒💼🌐

Lonza shuts down Swiss manufacturing site cutting 190 jobs
📢 Lonza is decommissioning its mammalian manufacturing site in Visp, Switzerland, after 30 years of operation. 🏭✅ This decision is driven by market dynamics and the need for flexibility. ❌ However, Lonza will focus on other sites and genecell therapies. 😔 Around 190 jobs will be lost.

